American Research & Management Company’s Teva Pharmaceuticals TEVA Stock Holding History

American Research & Management Company’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-105	Closed	-$3K	–	352
2018 Q2	$3K	Hold	105	–	–	﹤0.01%	305
2018 Q1	$2K	Hold	105	–	–	﹤0.01%	352
2017 Q4	$2K	Hold	105	–	–	﹤0.01%	353
2017 Q3	$2K	Hold	105	–	–	﹤0.01%	331
2017 Q2	$3K	Hold	105	–	–	﹤0.01%	318
2017 Q1	$3K	Sell	105 -400	-79%	-$13.7K	﹤0.01%	308
2016 Q4	$18K	Hold	505	–	–	0.01%	236
2016 Q3	$23K	Hold	505	–	–	0.01%	230
2016 Q2	$25K	Hold	505	–	–	0.01%	209
2016 Q1	$27K	Hold	505	–	–	0.01%	209
2015 Q4	$33K	Sell	505 -75	-13%	-$4.63K	0.01%	194
2015 Q3	$33K	Hold	580	–	–	0.01%	195
2015 Q2	$34K	Hold	580	–	–	0.01%	202
2015 Q1	$36K	Hold	580	–	–	0.01%	196
2014 Q4	$33K	Hold	580	–	–	0.01%	196
2014 Q3	$31K	Hold	580	–	–	0.01%	205
2014 Q2	$30K	Hold	580	–	–	0.01%	210
2014 Q1	$31K	Buy	580 +250	+76%	+$11.6K	0.01%	207
2013 Q4	$13K	Hold	330	–	–	﹤0.01%	279
2013 Q3	$12K	Hold	330	–	–	﹤0.01%	274
2013 Q2	$13K	Buy	+330	New	+$12.9K	0.01%	264

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

American Research & Management Company's TEVA Position: Q3 2018 in Review

American Research & Management Company sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 105 shares — an estimated $3K sold.

American Research & Management Company first reported a position in TEVA in Q2 2013 and held it in 21 quarters. The position peaked at $36K in Q1 2015. 557 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

American Research & Management Company reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
American Research & Management Company sold 105 Teva Pharmaceuticals shares in Q3 2018, an estimated $3K.
American Research & Management Company first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 21 quarters.
American Research & Management Company's Teva Pharmaceuticals position peaked at $36K in Q1 2015.
557 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on American Research & Management Company's 13F filing for Q3 2018, filed 4 Oct 2018.